The EPO published patent EP4043565A1 for modified heteronucleic acid compounds with IPC classification C12N 15/113 and A61K 31/713. The patent is assigned to Tokyo Medical and Dental University and Takeda Pharmaceutical Company Limited, with eight listed inventors. The technology covers nucleic acid modifications applicable to pharmaceutical development.\n\nPatent holders and licensees should review the granted claims to assess freedom-to-operate considerations for their therapeutic programs. No immediate compliance actions are required as this is an informational publication of a granted intellectual property right rather than a regulatory mandate.